Vaccine from type I diabetes passed the second phase of clinical trials

0
4
views

Second phase of clinical trials

In diabetes mellitus of the first type, the cells produce insulin are destroyed and no longer adjust the blood sugar level. For this reason, patients are forced to prickly prick insulin. Destruction occurs due to an error of the immune system, which aims against insulin producing cells. Swedish scientists from Linching University decided to find out whether it is possible to stop the attack of the immune system using a certain protein injection.

The team began to work with the GAD65 protein, against which the immune system often produces antibodies against the background of diabetes of the first type. They hoped to make an immune response more tolerant to stop damage to the production of cells.

In the second phase of studies, 109 volunteers were attended from 12 to 24 years, which were diagnosed during the previous six months. Scientists knew that genetic factors play an important role in the patient’s patient reaction, so they considered several variants of HLA genes that are associated with an increased risk of diabetes mellitus. For example, as an embodiment of HLA-DR3-DQ2, the patient’s body often generates antibodies against Gad65 at an early stage of the disease.

About half of the test participants had an option HLA-DR3-DQ2. All volunteers were injected with GAD65 protein into lymph nodes. Before therapy and 15 months after injection, scientists rated natural insulin production by the body.

The subgroup with the HLA-DR3-DQ2 genes did not lose insulin production as quickly as other patients showed observations. On the contrary, volunteers without this genetic variant there was no significant effect on treatment.

«Treatment with GAD65 seems simple, safe and promising way to maintain insulin production about half of the patients with diabetes mellitus of the first type,» said Johnny Ludwigsson. «We hope that further research will lead to the creation of a drug that can stop the progression of the disease.»

Modern methods of treating the first-type diabetes are directed to «system-wide» T-cell reactions, which is why the immune system gradually loses the ability to work fully combat other problems — viruses and bacteria. Recently scientists


We tell about the most interesting news and technologies — from the upcoming total automation to alternative energy, from artificial intelligence to the future medicine.

Hayk +